ClinicalTrials.gg
Sign In
Not yet recruitingNCT07892222Updated Oct 23, 2026

Stress Hyperglycemia Ratio and Glucose Variability in Critically Ill Patients

An observational study in Critical Illness and Hyperglycemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Assiut University · Observational

Updated Oct 23, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Study summary

This prospective cohort study aims to evaluate the stress hyperglycemia ratio and glucose variability among critically ill patients admitted to the intensive care unit.

Read the detailed description

Critical illness is often accompanied by stress-induced hyperglycemia and glucose fluctuations. The stress hyperglycemia ratio relates admission glucose to estimated average glucose derived from HbA1c, while glucose variability reflects fluctuations over time.

This observational study will calculate the stress hyperglycemia ratio and glucose variability indices from routine laboratory data in adult patients admitted to the intensive care unit and will record 28-day mortality.

02

Conditions studied

  • Critical Illness
  • Hyperglycemia

Keywords

  • Critically ill
  • Stress hyperglycemia ratio
  • Glucose variability
  • ICU mortality
  • Assiut
03

In context

Critical Illness

1,923 studies on the registry are indexed under Critical Illness; 465 are open to participants now.

This study's planned enrollment of 75 is below the median of 130 across 883 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Assiut University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients aged 18 years or older admitted to the intensive care unit at Assiut University Hospital with an expected stay of at least 24 hours.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older
  • Admitted to the ICU with expected stay of at least 24 hours
  • HbA1c and admission blood glucose obtainable within the first 24 hours
  • Written informed consent from the patient or legal guardian

Exclusion criteria

Exclusion Criteria:

  • - Age less than 18 years
  • Death or ICU discharge within 24 hours of admission
  • Pregnancy
  • Diabetic ketoacidosis or hyperosmolar hyperglycemic state at presentation
  • Conditions that falsely alter HbA1c
  • Fewer than 3 glucose measurements in the first 24 hours
  • Terminal illness with palliative or do-not-resuscitate decision
  • Refusal of consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Critically Ill Patients

    Adult patients admitted to the intensive care unit who will undergo calculation of stress hyperglycemia ratio and glucose variability indices.

06

What researchers measure

Primary outcomes

  1. Number of deaths

    Number of patients who die from any cause within 28 days from intensive care unit admission.

    Time frame: At 28 days

Secondary outcomes

  1. Stress hyperglycemia ratio

    Mean stress hyperglycemia ratio calculated as admission glucose divided by estimated average glucose derived from HbA1c.

    Time frame: Baseline

  2. Glucose coefficient of variation

    Mean coefficient of variation of glucose values calculated as standard deviation divided by mean glucose multiplied by 100.

    Time frame: At 24 hours

  3. ICU length of stay

    Mean length of stay in the intensive care unit in days.

    Time frame: At 28 days

  4. Number of patients requiring mechanical ventilation

    Number of patients who require invasive mechanical ventilation during the intensive care unit stay.

    Time frame: At 28 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 473 non-industry observational studies under Critical Illness, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 477 studies reached it within 22 months; a quarter within 11 and three quarters within 43.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2026
First posted
Oct 23, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Oct 20, 2027
CompletionEst.
Mar 10, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07892222
Lead sponsor
Assiut University
Responsible party
Andraws Hroun Abdou (Resident Physician, Department of Internal Medicine, Assiut University) — Principal investigator
First posted
Oct 23, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Oct 20, 2027 (estimated)
Completion
Mar 10, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Andraws H Abdo, Resident
Contact
andraws.18313318@med.aun.edu.eg
01554575509
Ahmed M Obaidullah, prof
study chair · Internal Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Critical Illness →

Other studies from this sponsor

Assiut University →

Start the discussion